Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Athira Pharma, Inc. | GENERAL COUNSEL | Common Stock | 51.9K | $29.4K | $0.57 | Sep 5, 2024 | Direct |
Athira Pharma, Inc. | GENERAL COUNSEL | Stock Option (Right to Buy) | 220K | Feb 14, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ATHA | Athira Pharma, Inc. | Sep 3, 2024 | 3 | $12K | 4 | Sep 5, 2024 | GENERAL COUNSEL |
ATHA | Athira Pharma, Inc. | Feb 14, 2024 | 1 | $0 | 4 | Feb 16, 2024 | GENERAL COUNSEL |
ATHA | Athira Pharma, Inc. | Jan 4, 2024 | 3 | $11.7K | 4/A | Feb 16, 2024 | GENERAL COUNSEL |
ATHA | Athira Pharma, Inc. | Jan 4, 2024 | 3 | $11.7K | 4 | Jan 8, 2024 | General Counsel |
ATHA | Athira Pharma, Inc. | Jan 19, 2023 | 1 | $0 | 4 | Jan 23, 2023 | General Counsel |
ATHA | Athira Pharma, Inc. | Jun 22, 2022 | 3 | $16.9K | 4 | Jun 24, 2022 | General Counsel |
ATHA | Athira Pharma, Inc. | Jan 18, 2022 | 1 | $0 | 4 | Jan 20, 2022 | General Counsel |
ATHA | Athira Pharma, Inc. | Nov 3, 2021 | 1 | $0 | 4 | Nov 5, 2021 | General Counsel |
ATHA | Athira Pharma, Inc. | Jun 1, 2021 | 0 | $0 | 3 | Jun 1, 2021 | General Counsel |